User login
Key clinical point: COVID-19 vaccines are safe and elicit a protective humoral response in most patients with multiple sclerosis (MS) who were treated with disease-modifying treatments (DMTs) or remained untreated, except for some patients treated with fingolimod or ocrelizumab.
Major finding: Overall, 86.8% of patients developed a positive humoral response against SARS-CoV-2, with only some patients treated with fingolimod (22.2%) or ocrelizumab (66%) failing to produce a significant humoral response (P < .01). Moreover, immunoglobulin G levels against SARS-CoV2 were significantly lower in patients treated with fingolimod or ocrelizumab than those treated with other DMTs or those who remained untreated (P < .01). None of the patients experienced any adverse events requiring hospitalization.
Study details: This was a prospective cohort study involving 140 patients with MS who were treated with different DMTs and had received vaccination for COVID-19 (mostly BNT162b2).
Disclosures: No source of funding was declared.
Source: Capone F et al. Neurotherapeutics. 2021 Dec 3. doi: 10.1007/s13311-021-01165-9.
Key clinical point: COVID-19 vaccines are safe and elicit a protective humoral response in most patients with multiple sclerosis (MS) who were treated with disease-modifying treatments (DMTs) or remained untreated, except for some patients treated with fingolimod or ocrelizumab.
Major finding: Overall, 86.8% of patients developed a positive humoral response against SARS-CoV-2, with only some patients treated with fingolimod (22.2%) or ocrelizumab (66%) failing to produce a significant humoral response (P < .01). Moreover, immunoglobulin G levels against SARS-CoV2 were significantly lower in patients treated with fingolimod or ocrelizumab than those treated with other DMTs or those who remained untreated (P < .01). None of the patients experienced any adverse events requiring hospitalization.
Study details: This was a prospective cohort study involving 140 patients with MS who were treated with different DMTs and had received vaccination for COVID-19 (mostly BNT162b2).
Disclosures: No source of funding was declared.
Source: Capone F et al. Neurotherapeutics. 2021 Dec 3. doi: 10.1007/s13311-021-01165-9.
Key clinical point: COVID-19 vaccines are safe and elicit a protective humoral response in most patients with multiple sclerosis (MS) who were treated with disease-modifying treatments (DMTs) or remained untreated, except for some patients treated with fingolimod or ocrelizumab.
Major finding: Overall, 86.8% of patients developed a positive humoral response against SARS-CoV-2, with only some patients treated with fingolimod (22.2%) or ocrelizumab (66%) failing to produce a significant humoral response (P < .01). Moreover, immunoglobulin G levels against SARS-CoV2 were significantly lower in patients treated with fingolimod or ocrelizumab than those treated with other DMTs or those who remained untreated (P < .01). None of the patients experienced any adverse events requiring hospitalization.
Study details: This was a prospective cohort study involving 140 patients with MS who were treated with different DMTs and had received vaccination for COVID-19 (mostly BNT162b2).
Disclosures: No source of funding was declared.
Source: Capone F et al. Neurotherapeutics. 2021 Dec 3. doi: 10.1007/s13311-021-01165-9.